Renal cell cancer (RCC) is a disease in which malignant cells form in the tubules of the kidney. RCC is the most common kidney malignancy in adults. There are 62,000 new cases of RCC in the United States per year with an estimated 14,000 deaths from the disease. Etiologic risk factors for RCC are discussed. Laboratory and radiologic studies to evaluate renal masses are reviewed including differential diagnosis. The treatment for RCC depends on the stage of disease at presentation. Options include surgical intervention, chemotherapy, biologic therapy and targeted therapy. Case studies are also presented.
Contact hours available until 10/26/17.
Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online CNE evaluation. You will be able to print your CNE certificate at any time after you complete the evaluation.
Planning Committee Disclosures:
• Gina Powley - Astellas/Medivation speaker bureau, Ferring Pharmaceuticals speaker bureau
• Leanne Schimke, MSN, CRNP, CUNP - Consultant: Bayer, Speaker's Bureau: Bayer
• Valre Welch, MSN, CPNP - Holister Continence Care Advisory Board; Speaker for Hollister Incontinence Workshops
Speaker Disclosures:
There are no disclosures to declare.
Commercial Support and Sponsorship:
No commercial support or sponsorship declared.
Accreditation Statement:
Society of Urologic Nurses and Associates is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
SUNA is a provider approved by the California Board of Registered Nursing, provider number, CEP 5556.
Objectives:
1. Describe the physical exam findings, laboratory and radiologic evaluation of patients with RCC.
2. Discuss surgical, radiologic, biologic response modifiers, and targeted therapy in RCC.
3. Name 3 antineoplastic agents used in the treatment of mRCC.